Add to Favorites
Methodology
Molecular
Test Description

Detection of internal tandem duplication and exon 20 tyrosine kinase domain (TKD) mutations using fragment-length analysis and bi-directional sequencing. Positive results identify specific TKD mutations or report ITD results quantitatively as allelic ratio. Testing may be performed on plasma to increase sensitivity.

This test is the NY-approved version of the FLT3 Mutation Analysis.

Clinical Significance

Testing for FLT3 and other gene mutations in AML patients with intermediate-risk cytogenetic abnormalities can improve risk stratification. The presence of an FLT3 mutation in a patient with AML implies aggressive disease.

Specimen Requirements
  • Peripheral blood: 5 mL in EDTA tube.
  • Bone marrow: 2 mL in EDTA tube.
Storage and Transportation

Use cold pack for transport, making sure cold pack is not in direct contact with specimen.

CPT Code(s)*
81245, 81246
Medicare MolDX CPT Code(s)*
81479
Turnaround Time

5 days

New York Approved
Yes
Level of Service
Global

*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payor being billed.